Background: Invasion of major hepatic vessels in hepatocellular carcinoma (HCC) generally prohibits the surgical treatment. Objective: Analyze outcomes of non-surgical approaches in this group of HCC. Methods: Retrospective review of medical records of 648 HCC admitted to King Chulalongkorn Memorial Hospital between January 2003 and December 2005 was carried out to select only patients who had unresectable HCC with vascular invasion and hepatic functions-Child-Pugh class-A. Vascular invasion was defined as involvement of portal vein, inferior vena cava (IVC), or their branches identified by imaging techniques. Non-surgical treatments were either transarterial chemoembolization (TACE) or systemic chemotherapy (SCT) in addition to general supportive care. Treatment outcomes of the patients were analyzed. Results: Out of 71 unresectable HCC patients enrolled, 57patients were treated with TACE, while 14 received SCT. In the TACE group, 39 (68%), 7 (12%) and 11 (19%) patients had portal vein, IVC, and both vessels invasion, respectively. In the SCT group; 11 (78%), 1 (7%) and 2 (14%) had invasion of portal vein, IVC, and both vessels, respectively. Median overall survival in both groups was 158 days. Univariate analysis demonstrated that AFP level <1000 ng/mL, tumor size <10 cm, and SCT treatment significantly influenced survival. Additional multivariate analysis confirmed that diameters of tumor, and SCT were independent prognostic factors for good survival. A survival analysis showed longer survival in the SCT group than that of TACE (210 vs. 149 days, p=0.03) group. Conclusion: Survival of HCC patients with major vessels invasion was better when treated with SCT compared to TACE. Future prospective study in larger populations to test the hypothesis is warranted.
Hepatocellular carcinoma (HCC) is the most common cancer with the highest incidence in Asia and Africa [1] . Surgical resection is still the mainstay of treatment but fewer than 20% of patients are suitable for surgery [2] . Inadequate liver reserve postresection or advanced disease due to large tumor, multiple lesions, bilobar tumor, and vascular invasion are the main contraindications to surgery [3] . In general, major vascular invasion is considered a relative or absolute contraindication to liver resection. Transarterial chemoembolization (TACE) is the palliative treatment that demonstrates the survival benefit in unresectable, especially large and multiple lesions HCC [4, 5] . However, it is not suitable in advanced HCC with vascular invasion, especially main portal vein involvement or with systemic metastasis [6] . In patients with good liver function, systemic chemotherapy (SCT) is another option but recent studies did not demonstrate any survival benefit in advanced-HCC patients [2] .
In this study, we analyzed outcome of nonsurgical treatment (TACE and SCT) in advanced-HCC patients with vascular invasion but with good liver functions in Thailand.
Memorial Hospital. The diagnosis of HCC was based on persistently-raised serum alpha-fetoprotein level (>400 ng/mL) in conjunction with characteristic finding based on computed tomography (SCT), magnetic resonance imaging (MRI) or angiographic imaging. Patients who did not meet clinical criteria had fine-needle aspiration cytology to confirm diagnosis. During this period, 310 HCC patients were treated by TACE or systemic chemotherapy, and their medical records were reviewed to select only the patients who had unresectable HCC with vascular invasion at the time of treatment and hepatic functionsChild-Pugh class-A. Exclusion criteria included patients who had liver resection after downstaging of tumor by TACE, vascular invasion developing after courses of treatment, or liver function of Child-Pugh class B or C. Vascular invasion was defined as involvement of portal vein, inferior vena cava (IVC), or their branches identified by imaging techniques showing presence of tumor thrombus or occlusion of main or major branches of portal vein or IVC. TACE was offered as the palliative treatment in the patients except when total occlusions of main portal vein or significant artery-vein shunting were present. Patients with systemic metastasis or patients who were not suitable for TACE, or in whom TACE failed to arrest the progression of disease, were treated by SCT. Survival duration was counted from the start of treatment in each group.
All data of patients included age, sex, comorbid disease-diabetes mellitus, viral hepatitis profile, complete blood count, coagulogram, liver function tests, alpha-fetoprotein, and imaging studies before treatment. Imaging data included tumor size, number, lobar distribution, site of vascular invasion, evidence of cirrhosis and distant metastasis. Serious complication or adverse effects associated with the treatments were also recorded. Survival outcomes in all patients were recorded and analyzed.
We compared the survival outcome between patients treated using TACE and SCT.
Statistical analysis
Data analysis was performed using the SPSS program. Median survival was estimated using KaplanMeier method. Cox-regression model with proportional hazards was used to analyze factors associated survival outcome.
Chi square test or Student t test was performed to compare baseline data between TACE and SCT groups. Difference of median survival between two groups was determined by the log-rank test, and survival plot graft was performed. P-value of less than 0.05 was considered statistically significant.
Results
Out of 310 HCC patients treated using TACE or SCT, 87 HCC patients had vascular invasion. Sixteen patients of this group were excluded due to failure of TACE, where no treatment in three cases, vascular invasion occurrence after TACE treatment in three cases, patient hepatic function Child-Pugh class B in three cases, and liver resection of tumor after downstaging by TACE in seven cases. Only 71 patients who had unresectable HCC with vascular invasion and with hepatic function Child Pugh class A were enrolled into this study. All patients had ECOG performance status 0-1.
There were 54 (76.0%) male patients and 17 (24.0%) female patients. Mean age was 55 years (range: 26-78 years). Fifty-seven patients were treated with TACE, and 14 received CT. Ten patients (14.0%) had diabetes. Nearly two-third of the patients had positive viral hepatitis-B marker, while eight patients (11.0%) had positive viral hepatitis-C marker, and 17 patients (24.0%) had none of B or C viral markers. Blood chemistries showed mean total bilirubin 1.16 mg/dL (range: 0.9-2.4 mg/dL), albumin 3.62 g/dL (range: 2.8-4.8 g/dL), prothrombin time 13.3 seconds (range: 11.0-18.5 seconds), and platelet count 268457 cell/mm 3 (range: 60000-572000 cell/mm 3) . Mean alphafetoprotein was 52639 IU/mL (range: 1.62-500000 IU/ mL). Imaging data showed unilobar tumor distribution in 53 patients (74.6%) and bilobar in 18 patients (25.4%).Tumor sizes ranged from 3 to 25 cm (mean: 11.5 cm). Numbers of tumors were between one and seven nodules (mean: 1.6 nodules). Six patients (8.5%) had previous history of rupture of tumor and 10 patients (14.5%) had lung metastasis.
Portal involvement only was found in 50 patients (70.4%). In this group, tumor was observed in the main portal vein in six patients. Only IVC involvement was demonstrated in eight patients (11.3%). Involvement of both portal vein and outflow vessels (hepatic vein, IVC or both) was shown in 13 patients (18.3%). IVC involvement was found in 16 patients (22.5%). Median overall survival was 158 days.
Alpha-fetoprotein <1000 IU/mL, tumor size <10cm, and SCT treatment influenced overall survival by univariate analysis as shown in Table 1 . However, Table 2 .
Patients and tumor characteristics of both TACE and SCT groups were summarized in Table 3 . The patient characteristics were not different between two groups. Cirrhosis was found in 34 patients (59.6%) of TACE and five patients (35.7%) of SCT group. Mean tumor size and numbers of tumor in TACE and SCT group were 11.47, 11.63 cm and 1.6, 1.7, respectively. Portal vein, IVC and both vascular invasion were demonstrated in 39 (68.4%), seven (12.3%), and 11 (19.3%) cases of TACE group and 11 (78.6%), one (7.1%), and two (14.3%) cases in SCT group. The main portal vein invasion was found in three patients (5.3%) patients in TACE group and three patients (21.4%) in SCT group. Bilobar tumor involvement was observed significantly more frequently in SCT group (50%) than in TACE group (19.3%). Lung metastasis was detected in five patients in each group (8.8% in TACE and 35.7% in SCT). In the five patients, TACE was employed because of marked abdominal discomfort. Most of them died within two months, thus, SCT had had not been offered. Four (7%) patients in TACE group, and two (14.3%) in SCT group had previous history of rupture tumor. Ten patients in TACE group had diabetes, and one patient in SCT group had hypertensive cardiomyopathy. 
P-value Hazard ratio
Treatment TACE was done by injection of 5 mL of an emulsion of lipiodol, 20 mg of mitomycin C and 500mgof 5-FU into feeding artery and followed by gelfoam embolization. TACE was performed every four to six weeks. CT (computed tomography) scanning was done to evaluate response three to four weeks after every sessions of TACE.
In SCT group, different regimens were employed. Nine cases received doxorubicin regimen that consisted of IV administration of doxorubicin maximum 60 mg/m 2 on day one every four weeks. One patient received doxorubicin plus gemcitabine. Two patients received gemcitabine 1000 mg/m 2 on day1 plus oxaliplatin 100 mg/m 2 on day 2 every two weeks, and after completion, doxorubicin regimen was added in one patient. One patient received six courses of doxorubicin regimen followed by cisplatinum 60 mg/m 2 on day 1 every four weeks. Treatment was repeated until disease progression, unacceptable toxicity was detected, or up to maximum six cycles. Only one patient received capecitabine 1000 mg/m 2 orally twice daily of two weeks followed by a oneweek rest for 13 cycles. Dosage of the subsequent cycles was adjusted according to prior liver function test and the toxic effects that developed during the preceding cycle. All patients received standard supportive regimen consisting of hydration and antiemetics.
Patients in TACE group received one to eight treatment sessions (median 2). In SCT group, nine patients had at least a session of TACE before treatment (range: 1-4 sessions, median 1).
Liver function deterioration occurred in two patients of TACE group. Both of them had main portal vein invasion and died within a month. Postembolization syndrome in one patient required admission after a session of TACE. In SCT group, only one patient developed febrile neutropenia after one course of doxorubicin. 
